ABSTRACT: Susceptibility to metabolism is a common issue with the tert-butyl group on compounds of medicinal interest. We demonstrate an approach of removing all the fully sp 3 C−Hs from a tert-butyl group: replacing some C−Hs with C−Fs and increasing the s-character of the remaining C−Hs. This approach gave a trifluoromethylcyclopropyl group, which increased metabolic stability. Trifluoromethylcyclopropyl-containing analogues had consistently higher metabolic stability in vitro and in vivo compared to their tert-butyl-containing counterparts.
C ompounds with high metabolic lability or hepatic clearance often have low oral bioavailability and short halflives. Consequently, optimization of the metabolic stability of lead molecules is of critical importance in the drug discovery process. 1 In vitro studies such as metabolic stability assays in liver microsomes, 2 biotransformation studies to pinpoint vulnerable spots in the molecule, and in vivo pharmacokinetic studies in preclinical species are some of the tools employed by project teams to arrive at potent compounds with favorable clearance values. Cytochrome P450s (CYPs) are the principal enzymes considered responsible for hepatic metabolism. 3, 4 Susceptibility to metabolism is a common issue with the tertbutyl group on compounds of medicinal interest. During the course of a lead optimization effort, we encountered a pocket in a receptor with a strong preference for a tert-butyl group. However, compounds bearing this tert-butyl group had high clearance in rats and microsomal incubations. The general principals and specific functional group used during the course of overcoming this challenge may be employed in other chemical series and are detailed herein.
We hypothesized that the rapid abstraction of H from the sp 3 hybridized methyl carbons of the tert-butyl resulted in rapid oxidative metabolism. Compound 1 served as the prototype tert-butyl-containing compound. An in vitro biotransformation study in rat and human liver microsomes (RLM, HLM) showed that the major route of metabolism of 1 is oxidation of the tertbutyl to the corresponding alcohol product 2, confirming the initial hypothesis. Further in vitro studies in human liver microsomes suggested that oxidative metabolism could be attributed to multiple Cytochrome P450 isoform involvement, including CYPs 3A4/5, 2D6, 2C9, and 1A2 (data not shown). Polar substitution has often been used to increase metabolic stability. As expected, analogues bearing a hydroxyl, 2, cyano, 3, or acid, 4, had increased microsomal stability. However, an oxetane, another group that has recently been reported to improve metabolic stability, 5−8 offered no improvement (5 vs 1). Clearly, in some instances, the introduction of a polar group is not tolerated by the receptor. For such a case, another solution was needed. We hypothesized that removing all fully sp 3 C−Hs from the tert-butyl would lower the rate of H-abstraction by metabolizing enzymes. On the basis of this principle, we designed a replacement for tert-butyl that has a similar shape and size and retains hydrophobicity but lacks fully sp 3 C−Hs. One of the methyl groups was replaced by CF 3 . The other two methyl groups were joined to form a cyclopropyl ring, whose C−Hs have a higher homolytic bond dissociation energy owing to the higher s-character of the C−H bonding orbitals than a typical aliphatic C−H. As shown by comparing compounds 1, 6, and 7, the CF 3 group alone was not adequate nor was just installing the cyclopropyl group (1 vs 8). However, when both features were combined in the trifluoromethylcyclopropyl 9−11 group or Cp-CF 3 , the resulting compound 9 had high metabolic stability. The LogP of compounds 1 and 9 are 4.2 and 4, respectively. Compound 10 bears the Cp-CF 3 and also incorporates a pyridyl-N, which can be useful as a solubilizing functionality.
We sought to probe the consistency of increase in metabolic stability of the Cp-CF 3 group compared to tert-butyl. To do so, we tested the metabolic stability of six additional matched pairs of biaryls and amides, where the portion of the compound distal to the tert-butyl or Cp-CF 3 contained functionality that was generally relatively metabolically stable. The results are summarized in Table 2 and demonstrate consistent increases in metabolic stability by replacing tert-butyl with Cp-CF 3 . Compounds 1, 5, 6, 9, 11, 12, 19 , and 20 were checked for CYP 3A4/5 inhibition with and without a 30 min incubation with NADPH prior to substrate addition as a screen for potential time-dependent inhibition, in order to mitigate against a chance for artifacts in metabolic stability differences due to CYP inhibition. All compounds tested had negligible reversible CYP inhibition (IC 50 >50 μM) with no evidence of time-dependent inhibition.
We measured clearance in rats for representative compounds in order to determine if the in vitro clearance comparisons were consistent with in vivo results. The results are summarized in Table 3 . Despite the addition of a polar atom, oxetane-containing 5 had similar in vivo clearance to tert-butyl-containing 1, consistent with the lack of in vitro improvement. Cp-CF 3 -containing 9 and 12 had substantially lower in vivo clearance than their tert-butyl-containing counterparts 1 and 11, respectively.
Finasteride (23) is known to be metabolized in humans predominantly on the tert-butyl (ω) but also at the 6-position (Figure 1) . 12, 13 Replacing the tert-butyl with Cp-CF 3 increased the t 1/2 in HLM from 63 min (23) to 114 min (24). This moderate increase is consistent with a caveat of the approach: replacing tert-butyl with Cp-CF 3 is not expected to substantially reduce metabolism at distal soft-spots. 14 In this case, at least the 6-position can still be metabolically labile. 12, 13 In conclusion, we have demonstrated an approach of removing all the fully sp 3 C−Hs from a tert-butyl group: replacing some H with F and increasing the s-character of the remaining C−Hs. This approach gave a trifluoromethylcyclopropyl group that consistently increased metabolic stability in vitro and in vivo compared to tert-butyl.
■ EXPERIMENTAL PROCEDURES
The compounds 1−22 were prepared according to Scheme 1. 
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Biotransformation
For metabolite ID, compound was incubated with rat liver microsomes for 30 min using similar conditions as the CYP stability test. Samples were precipitated with 1.5 x volumes of 100% acetonitrile followed by 10 min centrifugation at 4000g. 10µl of supernatant was analyzed by LC/MS/MS in a TSQ Quantum Ultra® Mass Spectrometer (Thermo Fisher Scientific, Waltham MA) in H-ESI positive mode. A Waters XTerra® MS C18 5µM particle size 4.6x150 mm with MS C18 5µM Waters Sentry® Guard Column was used for separation of parent and metabolites. The following reverse phase LC conditions were used: mobile phase A = H 2 O+0.1% formic acid; mobile phase B = acetonitrile + 0.1% formic acid; flow = 1 mL/min; gradient ramp from 5% B at 1 min to 95% B over 21 min (25 min total run time). Authentic standards were used to develop specific SRM methods for parent compounds, as well as putative metabolites. Specific retention time, UV absorption spectra and product ion spectra of compounds and metabolites (authentic standards and assay produced metabolites) were analyzed to confirm compound identities.
CYP Inhibition
Reversible and time-dependent CYP inhibition (TDI) was assessed with human liver microsomes in an "IC 50 -shift" approach [Obach et al, 2007] . Briefly, test compounds were first pre-incubated at 37 o C, with human liver microsomes (0.1 mg/mL) suspended in 100 mM potassium phosphate buffer, pH 7.4, supplemented with 5 mM MgCl 2 plus or minus 1 mM NADPH. Each compound was examined at 7 concentrations, ranging from 0.14 to 100 µM in the pre-incubation to evaluate the dose-response. After 30 min, all pre-incubations were then combined with an equal volume of 100 mM phosphate buffer, pH 7.4, containing 1 mM NADPH and selective CYP 3A4/5 probe substrate, midazolam (2 µM). This dilution step generated a final incubation mixture of 0.05 mg/mL human liver micosomes, 0.07-50 µM test compound and 1 µM midazolam that was incubated an additional 10 min at 37 o C. This final reaction (100 µL) was terminated through addition of 185 µL of acetonitrile containing [ 13 C 3 ]-1'-hydroxymidazolam as MS internal standard and supernatants were prepared for bioanalysis essentially as described above. Bioanalysis of 1'-hydroxymidazolam formation in each reaction well was determined as previously reported [Brown et al, 2009 ].
Each IC 50 was derived from an 8-point dose-response (including a 0 µM reference incubation) tested in singlet, and % CYP 3A4/5 inhibition for each reaction was determined relative to a 0 µM reference incubation used to define 100% of midazolam 1'-hydroxylation activity. A linear-log transformation of % inhibition versus test article concentration was fit with a 4-parameter, one-site dose-response curve using XLFit. The IC 50 that is derived from the pre-incubation lacking NADPH is taken as the measure of competitive, reversible CYP inhibition. For each compound, the ratio of IC 50 derived from pre-incubations lacking NADPH versus pre-incubations containing NADPH was used as an indicator of CYP 3A4/5 TDI, where a ratio >2 is indicative of TDI. 
CYP Reaction Phenotyping
The Cytochrome P450 (CYP) Reaction Phenotyping (RP) Assay is designed to assess the relative metabolic clearance contribution of five major human CYP drugmetabolizing isoforms (3A, 2D6, 2C9, 1A2 and 2C19) to the metabolism of new chemical entities (NCEs) in Human Liver Microsomes (HLM). These five isoforms contribute to the biotransformation of about 90% marketed drugs subjected to human CYP metabolism [Guengerich, 2004] . The assay described here uses the parent depletion approach [Lau 2002 , Obach 1999 , Obach 1997 . The condition for achieving isoform-selective inhibition is through addition in combination of selective chemical inhibitors and/or monoclonal antibodies (mAb) to knock out individual CYP activities to inhibit each of the five major CYPs isoforms (3A, 2D6, 2C9, 1A2, 2C19) by >90% while generating <20% "off-target" CYP inhibition. The contribution of each of the major CYPs to microsomal clearance of a new chemical entity (NCE) can be measured. This is done by evaluating the reduction in intrinsic clearance (CL int ) observed in selectively inhibited CYP incubations relative to the uninhibited control CL int , reported as a "% Clearance Inhibition" (%CL Inh) for each of the five major CYP isoforms outlined above. The observation of a high %CL Inh associated with a particular CYP isoform is indicative of a high contribution from that CYP isoform in the NCE metabolism.
[Guengerich FP (2004) 
Spectral data
Analytic HPLC method: Atlantis 4.6x150 mm 0-95% acetonitrile/water 0.1% trifluoroacetic acid in 19 min. Purity by HPLC UV was >99% for all products. LCMS method: 3 mm x 33 mm Intersil C8-3 reverse phase, 3.0 µm particle size running a gradient of 5-95% MeCN/water (5 mM ammonium formate) over a period of 2 min at a flow rate of 4 mL/min at 40 °C; DAD-UV detection, 220-600 nm. HRMS data was collected using a Waters LCT Premier mass spectrometer with dual electrospray ionization source and Waters Acquity UPLC. The resolution of the MS system was approximately 12000 (FWHM definition). 
4-(1-(trifluoromethyl)cyclopropyl)phenylboronic acid:
To 1-bromo-4-(1-(trifluoromethyl)cyclopropyl)benzene (5.0 g, 19 mmol) in THF (50 mL) at -78 °C was added butyllithium (13 mL, 21 mmol). After stirring 1h, trimethylborate (3.15 mL, 28.3 mmol) was added. After warming to room temp, the THF was removed in vacuo. The solid residue was taken up in water and extracted with ether to remove non-polar impurities. The aqueous layer was acidified and extracted with ethyl acetate. The organic layer was washed with saturated sodium chloride, dried over sodium sulfate, filtered and concentrated to dryness to afford pure 4-(1-(trifluoromethyl)cyclopropyl)phenylboronic acid (3.12 g, 72%). General procedure for the synthesis of compounds 1-10, 19-22: The arylboronic acid was stirred with 1 eq of the aryl halide, 0.06 eq of dicyclohexyl(2',6'-dimethoxybiphenyl-2-yl)phosphine (SPhos), 0.03 eq of Pd(OAc) 2 and 3 eq potassium phosphate in THF until the reaction was judged complete by LCMS, then filtered and purified by HPLC (acetonitrile/water with 0.1% ammonium hydroxide). 48, 154.19, 152.46, 139.72, 134.56, 127.14, 126.07, 119.64, 117.13, 107.47, 34.89, 31.20 6-(4-(1-hydroxy-2-methylpropan-2-yl)phenyl)nicotinonitrile (2): 2-(4-(5-cyanopyridin-2-yl)phenyl)-2-methylpropanoic acid (20 mg, 0.075 mmol) was stirred in methylene chloride (1 mL) and oxalyl chloride (1 mL) for 3 hr, then evaporated to dryness. The residue was dissolved in THF (1 mL), cooled to 0 °C, and sodium borohydride (14 mg, 0.37 mmol) was added. 55, 152.54, 143.93, 140.02, 136.95, 127.96, 125.90, 124.11, 119.97, 116.89, 108.19, 37.20, 29.06 43, 160.04, 152.46, 146.68, 139.96, 135.98, 127.52, 126.66, 119.99, 116.96, 107.91, 77.22, 26.24 07, 152.51, 149.25, 139.91, 135.51, 127.67, 125.88, 119.81, 117.02, 107.82, 83.54, 43.46, 27.64 55, 152.45, 151.95, 139.78, 134.95, 127.43, 127.24, 119.69, 117.16, 107.44, 34.06, 23.82 6-(4-(1,1,1-trifluoropropan-2-yl)phenyl)nicotinonitrile (7)
6-(4-tert
A. 6-(4-chlorophenyl)nicotinonitrile: To 4-chlorophenylboronic acid (64.1 mg, 0.410 mmol), 2-bromo-5-cyanopyridine (75 mg, 0.41 mmol), and potassium phosphate (261 mg, 1.23 mmol) in THF (0.5 mL) under nitrogen was added tetrakis(triphenylphosphine)palladium(0) (23.7 mg, 0.0205 mmol) in THF (0.5 mL) under nitrogen. The reaction mixture was stirred at 100 °C until it was judged complete by LCMS, and then filtered and purified by HPLC to afford 19 mg (22%) 6-(4-chlorophenyl)nicotinonitrile. (4-(3,3,3-trifluoroprop-1-en-2-yl)phenyl) nicotinonitrile: To a mixture of 6-(4-chlorophenyl)nicotinonitrile (16.4 mg, 0.0764 mmol), 4,4,6-trimethyl-2-(3,3,3-trifluoroprop-1-en-2-yl)-1,3,2-dioxaborinane (33.9 mg, 0.153 mmol), and potassium phosphate (48.7 mg, 0.229 mmol) in THF (1 mL) was added a premixed solution of SPhos (1.9 mg, 4.6 µmol) and palladium acetate (0.5 mg, 2 µmol). The reaction mixture was stirred at 120 °C with microwave irradiation for 20 min. After the reaction mixture was judged complete by LCMS, it was filtered and purified by HPLC to afford 6 mg (29%) 6-(4-(3,3,3-trifluoroprop-1-en-2-yl)phenyl)nicotinonitrile.
B. 6-
C. 6-(4-(1,1,1-trifluoropropan-2-yl)phenyl)nicotinonitrile: To 6-(4-(3,3,3-trifluoroprop-1-en-2-yl)phenyl)nicotinonitrile (6 mg, 0.02 mmol) in EtOAc (1 mL) and THF (1 mL) a was added 5 mg Pd(OH) 2 /C. The reaction vessel was evacuated and flushed with hydrogen. The reaction mixture was stirred until it was judged complete by LCMS. The reaction mixture was filtered and purified by HPLC to afford 3.4 mg (56%) 6-(4-(1,1,1-trifluoropropan-2-yl)phenyl)nicotinonitrile.
